NICE clinical guidelines
Issued: March 2011
CG117

Tuberculosis: Clinical diagnosis and management of tuberculosis, and measures for its prevention and control

This is an extract from the guidance. The complete guidance is available at guidance.nice.org.uk/cg117

Introduction

This guideline updates and replaces 'Tuberculosis: clinical diagnosis and management of tuberculosis and measures for its prevention and control' (NICE clinical guideline 33).

The incidence of TB is influenced by risk factors such as exposure to, and susceptibility to, TB and levels of deprivation (poverty, housing, nutrition and access to healthcare), and differs in different parts of England and Wales. Where scientific evidence supports it, this guideline makes recommendations on service organisation, as well as for individual teams of healthcare professionals. The guideline aims to focus NHS resources where they will combat the spread of TB, and some sections deal with high- and low-incidence areas separately.

The guideline is designed for use in the National Health Service in England and Wales. Readers in other countries, particularly where the incidence of TB is higher, should exercise caution before applying the recommendations.

New recommendations on using interferon-gamma tests for the diagnosis of latent tuberculosis (TB) have been added.

Recommendations are marked as [2006], [2006, amended 2011] or [new 2011].

  • [2006] indicates that the evidence has not been updated and reviewed since the original guideline.

  • [2006, amended 2011] indicates that the evidence has not been updated and reviewed since 2006 but a small amendment has been made to the recommendation.

  • [new 2011] indicates that the evidence has been reviewed and the recommendation has been updated or added.